Tatva Chintan Pharma Chem Limited | Small-cap | Basic Materials
₹917.35
1.84%
| Tatva Chintan Pharma Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 3.8B
Gross Profit 1.8B 48.02%
Operating Income 65.5M 1.71%
Net Income 57.1M 1.49%

Balance Sheet Metrics

Total Assets 8.4B
Total Liabilities 974.2M
Shareholders Equity 7.4B
Debt to Equity 0.13

Cash Flow Metrics

Revenue & Profitability Trend

Tatva Chintan Pharma Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 3.8B 3.9B 4.2B 4.3B 3.0B
Cost of Goods Sold 2.0B 1.8B 2.3B 2.1B 1.6B
Gross Profit 1.8B 2.1B 1.9B 2.2B 1.4B
Operating Expenses 966.4M 838.9M 759.7M 820.5M 461.7M
Operating Income 65.5M 441.2M 587.4M 1.0B 600.4M
Pre-tax Income 75.8M 435.7M 447.8M 1.0B 607.0M
Income Tax 18.7M 132.1M -7.1M 82.5M 84.3M
Net Income 57.1M 303.5M 454.9M 958.7M 522.6M
EPS (Diluted) - ₹13.26 ₹20.52 ₹44.59 ₹23.58

Income Statement Trend

Tatva Chintan Pharma Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets 2.7B 3.0B 3.1B 4.4B 1.8B
Non-Current Assets 5.7B 5.2B 4.5B 2.2B 1.3B
Total Assets 8.4B 8.2B 7.6B 6.6B 3.1B
Liabilities
Current Liabilities 960.3M 796.6M 2.4B 1.7B 1.2B
Non-Current Liabilities 14.0M 19.7M 53.8M 137.7M 308.2M
Total Liabilities 974.2M 816.4M 2.4B 1.8B 1.5B
Equity
Total Shareholders Equity 7.4B 7.4B 5.1B 4.7B 1.7B

Balance Sheet Composition

Tatva Chintan Pharma Cash Flow Statement

No cash flow data available.

Tatva Chintan Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 384.07
Forward P/E 35.10
Price to Book 2.99
Price to Sales 5.77
PEG Ratio 35.10

Profitability Ratios

Profit Margin 1.49%
Operating Margin 1.57%
Return on Equity 0.77%
Return on Assets 0.50%

Financial Health

Current Ratio 2.76
Debt to Equity 4.93
Beta 0.17

Per Share Data

EPS (TTM) ₹2.46
Book Value per Share ₹315.61
Revenue per Share ₹163.46

Financial data is updated regularly. All figures are in the company's reporting currency.